Colon perforation during antiangiogenic therapy for malignant glioma

Neuro-Oncology

Volumn 11, Issue 1, 2009, Pages 92-95

  Norden, Andrew D ^a,b,c   Drappatz, Jan ^a,b,c   Ciampa, Abigail Slate ^b   Doherty, Lisa ^b   Lafrankie, Debra Conrad ^b   Kesari, Santosh ^a,b,c   Wen, Patrick Y ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antiangiogenic drugs; Bevacizumab; Gastrointestinal perforation; Malignant glioma

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CEDIRANIB; CORTICOSTEROID DERIVATIVE; DEXAMETHASONE; IRINOTECAN; PAZOPANIB; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; VANDETANIB; VATALANIB;

ABDOMINAL PAIN; ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; ASTROCYTOMA; CANCER RADIOTHERAPY; COLON RESECTION; COLOSTOMY; CONTROLLED STUDY; DIGESTIVE SYSTEM INFLAMMATION; DIGESTIVE SYSTEM PERFORATION; DIVERTICULITIS; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLIOBLASTOMA; GLIOMA; HUMAN; LAPAROTOMY; MAJOR CLINICAL STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; GLIOMA; HUMANS; INTESTINAL PERFORATION; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME;

EID: 61449257404     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-071     Document Type: Article

References (17)

1. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17:2572-2578.
2. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13:1253-1259.
3. Cloughesy T, Prados M, Wen P, et al. A phase II, randomized, non- comparative clinical trial of bevacizumab alone or in combination with CPT-11 prolongs 6-month PFS in recurrent, treatment-refractory glioblastoma. Presented at: Society for Neuro-Oncology 12th Annual Meeting; November 15-18, 2007; Dallas, TX.
4. Cloughesy TF, Prados MD, Mikkelsen T, et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) [abstract]. J Clin Oncol. 2008;26:2010b.
5. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83-95.
6. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
7. Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol. 2007;14:1860-1869.
8. Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol. 2007; 105:3-6.
9. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005;23:8033-8040.
10. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24:5201-5206.
11. Badgwell BD, Camp ER, Feig B, et al. Management of bevacizumab- associated bowel perforation: a case series and review of the literature. Ann Oncol. 2008;19:577-582.
12. Heinzerling JH, Huerta S. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg. 2006;63:334-337.
13. Sugrue M, Kozloff M, Hainsworth J, et al. Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol. 2006;24:3535.
14. Weiner HL, Rezai AR, Cooper PR. Sigmoid diverticular perforation in neurosurgical patients receiving high-dose corticosteroids. Neurosur- gery. 1993;33:40-43.
15. Fadul CE, Lemann W, Thaler HT, Posner JB. Perforation of the gastrointestinal tract in patients receiving steroids for neurologic disease. Neurology. 1988;38:348-352.
16. Mpofu S, Mpofu CM, Hutchinson D, Maier AE, Dodd SR, Moots RJ. Steroids, non-steroidal anti-inflammatory drugs, and sigmoid diverticular abscess perforation in rheumatic conditions. Ann Rheum Dis. 2004;63:588-590.
17. Koehler PJ. Use of corticosteroids in neuro-oncology. Anticancer Drugs. 1995;6:19-33.